Down-regulation of genes in the lysosomal and ubiquitin-proteasome proteolytic pathways in calpain-3-deficient muscle

International Journal of Biochemistry and Cell Biology

Volumn 35, Issue 5, 2003, Pages 676-684

  Combaret, Lydie ^a   Béchet, Daniel ^a   Claustre, Agnès ^a   Taillandier, Daniel ^a   Richard, Isabelle ^b   Attaix, Didier ^a  

^a CEMAGREF   (France)

^b GÉNÉTHON   (France)

Author keywords

Calpain 3; Cathepsins; Protein breakdown; Skeletal muscle; Ubiquitin proteasome system

Indexed keywords

CALPAIN 3; CATHEPSIN B; CATHEPSIN L; MESSENGER RNA; PROTEASOME; UBIQUITIN;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; GASTROCNEMIUS MUSCLE; GENE EXPRESSION; IN VITRO STUDY; KNOCKOUT MOUSE; LYSOSOME; MEASUREMENT; MOUSE; MUSCLE MASS; NONHUMAN; PATHOPHYSIOLOGY; PROTEIN DEFICIENCY; PROTEIN DEGRADATION; SKELETAL MUSCLE;

EID: 0037401984     PISSN: 13572725     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1357-2725(02)00357-6     Document Type: Article

References (41)

1. Adegoke O.A., Bedard N., Roest H.P., Wing S.S. Ubiquitin-conjugating enzyme E214k/HR6B is dispensable for increased protein catabolism in muscle of fasted mice. American Journal of Physiology and Endocrinology Metabolism. 283:2002;E482-E489.
2. 2+-dependent systems. In E. E. Bittar & A. J. Rivett (Eds.), Intracellular protein degradation (pp. 235-266). Greenwich, CT: JAI Press Inc.
3. Baghdiguian S., Martin M., Richard I., Pons F., Astier C., Bourg N., Hay R.T., Chemaly R., Halaby G., Loiselet J., Anderson L.V., Lopez de Munain A., Fardeau M., Mangeat P., Beckmann J.S., Lefranc G. Calpain 3 deficiency is associated with myonuclear apoptosis and profound perturbation of the IκBα/NFκB pathway in limb-girdle muscular dystrophy type 2A. Nature Medicine. 5:1999;503-551.
4. Baghdiguian S., Richard I., Martin M., Coopman P., Beckmann J.S., Mangeat P., Lefranc G. Pathophysiology of limb girdle muscular dystrophy type 2A: hypothesis and new insights into the IκBα/NFκB survival pathway in skeletal muscle. Journal of Molecular Medicine. 79:2001;254-261.
5. Baracos V.E., DeVivo C., Hoyle D.H.R., Goldberg A.L. Activation of the ATP-ubiquitin-proteasome pathway in skeletal muscle of cachectic rats bearing a hepatoma. American Journal of Physiology. 268:1995;E996-1006.
6. Béchet D.M., Ferrara M.J., Mordier S.B., Roux M.P., Deval C.D., Obled A. Expression of lysosomal cathepsin B during calf myoblast-myotube differentiation. Characterization of a cDNA encoding bovine cathepsin B. Journal of Biological Chemistry. 266:1991;14104-14112.
7. Béchet D.M., Listrat A., Deval C., Ferrara M., Quirke J.F. Cimaterol reduces cathepsin activities but has no anabolic effect in cultured myotubes. American Journal of Physiology. 259:1990;E822-E827.
8. Campbell K.P. Three muscular dystrophies: loss of cytoskeleton-extracellular matrix linkage. Cell. 80:1995;675-679.
9. Chomczynski P., Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Analytical Biochemistry. 162:1987;156-159.
10. Ciechanover A., Gonen H., Bercovich B., Cohen S., Fajerman I., Israel A., Mercurio F., Kahana C., Schwartz A.L., Iwai K., Orian A. Mechanisms of ubiquitin-mediated, limited processing of the NFκB1 precursor protein p105. Biochimie. 83:2001;341-349.
11. Combaret L., Taillandier D., Voisin L., Samuels S.E., Boespflug-Tanguy O., Attaix D. No alteration in gene expression of components of the ubiquitin-proteasome proteolytic pathway in dystrophin-deficient muscles. FEBS Letters. 393:1996;292-296.
12. Combaret L., Tilignac T., Claustre A., Voisin L., Taillandier D., Obled C., Tanaka K., Attaix D. Torbafylline (HWA 448) inhibits enhanced skeletal muscle ubiquitin-proteasome-dependent proteolysis in cancer and septic rats. Biochemical Journal. 361:2002;185-192.
13. Deval C., Mordier S., Obled C., Béchet D., Combaret L., Attaix D., Ferrara M. Identification of cathepsin L as a differentially expressed message associated with skeletal muscle wasting. Biochemical Journal. 360:2001;143-150.
14. Fardeau M., Eymard B., Mignard C., Tome F.M., Richard I., Beckmann J.S. Chromosome 15-linked limb-girdle muscular dystrophy: clinical phenotypes in Reunion Island and French metropolitan communities. Neuromuscular Disorders. 6:1996;447-453.
15. Hobler S.C., Tiao G., Fischer J.E., Monaco J., Hasselgren P.O. Sepsis-induced increase in muscle proteolysis is blocked by specific proteasome inhibitors. American Journal of Physiology. 274:1998;R30-R37.
16. Huang J., Forsberg N.E. Role of calpain in skeletal-muscle protein degradation. Proceedings of the National Academy of Sciences of the United States of America. 95:1998;12100-12105.
17. Jagoe R.T., Goldberg A.L. What do we really know about the ubiquitin-proteasome pathway in muscle atrophy? Current Opininon in Clinical Nutrition and Metabolic Care. 4:2001;183-190.
18. Jagoe R.T., Lecker S.H., Gomes M., Goldberg A.L. Patterns of gene expression in atrophying skeletal muscles: response to food deprivation. FASEB Journal. 16:2002;1697-1712.
19. Kawai H., Yoneda K., Naruo T., Nishida Y., Kashiwagi S., Kunishige M., Saito S. Lysosomal enzyme activities in skeletal muscle of patients with neuromuscular diseases. Muscle & Nerve. 18:1995;1009-1015.
20. Kominami E., Bando Y., Ii K., Hizawa K., Katunuma N. Increases in cathepsins B and L and thiol proteinase inhibitor in muscle of dystrophic hamsters. Their localization in invading phagocytes. Journal of Biochemistry. 96:1984;1841-1848.
21. Lecker S.H., Solomon V., Price S.R., Kwon Y.T., Mitch W.E., Goldberg A.L. Ubiquitin conjugation by the N-end rule pathway and mRNAs for its components increase in muscles of diabetic rats. Journal of Clinical Investigation. 104:1999;1411-1420.
22. Lowell B.B., Ruderman N.B., Goodman M.N. Evidence that lysosomes are not involved in the degradation of myofibrillar proteins in rat skeletal muscle. Biochemical Journal. 234:1986;237-240.
23. MacLennan P.A., McArdle A., Edwards R.H.T. Effects of calcium on protein turnover of incubated muscles from mdx mice. American Journal of Physiology. 260:1991;E594-E598.
24. 2+-activated, and ATP-ubiquitin-dependent proteolytic pathways in skeletal muscle from head trauma patients. Proceedings of the National Academy of Sciences of the United States of America. 93:1996;2714-2718.
25. Mason R.W. Lysosomal metabolism of proteins. Subcellular Biochemistry. 27:1996;159-190.
26. Pickart C.M. Targeting of substrates to the 26S proteasome. FASEB Journal. 11:1997;1055-1066.
27. Poussard S., Duvert M., Balcerzak D., Ramassamy S., Brustis J.J., Cottin P., Ducastaing A. Evidence for implication of muscle-specific calpain (p94) in myofibrillar integrity. Cell Growth & Differentiation. 7:1996;1461-1469.
28. Price S.R., England B.K., Bailey J.L., Van Vreede K., Mitch W.E. Acidosis and glucocorticoids concomitantly increase ubiquitin and proteasome subunit mRNAs in rat muscle. American Journal of Physiology. 267:1994;C955-C960.
29. Rabbani N., Moses L., Anandaraj M.P. Calcium-activated neutral protease and its endogenous inhibitor in tissues of dystrophic and normal mice. Biochemical Medicine and Metabolic Biology. 37:1987;282-286.
30. Richard I., Broux O., Allamand V., Fougerousse F., Chiannilkulchai N., Bourg N., Brenguier L., Devaud C., Pasturaud P., Roudaut C., Hillaire D., Passos-Bueno M.R., Zatz M., Tischfield J.A., Fardeau M., Jackson C.E., Cohen D., Beckmann J.S. Mutations in the proteolytic enzyme calpain 3 cause limb-girdle muscular dystrophy type 2A. Cell. 81:1995;27-40.
31. Richard I., Roudaut C., Marchand S., Baghdiguian S., Herasse M., Stockholm D., Ono Y., Suel L., Bourg N., Sorimachi H., Lefranc G., Fardeau M., Sebille A., Beckmann J.S. Loss of calpain 3 proteolytic activity leads to muscular dystrophy and to apoptosis-associated IκBα/NFκB pathway perturbation in mice. Journal of Cellular Biology. 151:2000;1583-1590.
32. Sorimachi H., Imajoh-Ohmi S., Emori Y., Kawasaki H., Ohno S., Minami Y., Suzuki K. Molecular cloning of a novel mammalian calcium dependent protease distinct from both m- and μ-types. Specific expression of the mRNA in skeletal muscle. Journal of Biological Chemistry. 264:1989;20106-20111.
33. Sorimachi H., Ishiura S., Suzuki K. Structure and physiological function of calpains. Biochemical Journal. 328:1997;721-732.
34. 2+-activated and ATP-ubiquitin-dependent proteinases in the unweighted rat soleus muscle. Biochemical Journal. 316:1996;65-72.
35. Temparis S., Asensi M., Taillandier D., Aurousseau E., Larbaud D., Obled A., Béchet D., Ferrara M., Estrela J.M., Attaix D. Increased ATP-ubiquitin-dependent proteolysis in skeletal muscles of tumor-bearing rats. Cancer Research. 54:1994;5568-5573.
36. Tilignac T., Temparis S., Combaret L., Taillandier D., Pouch M.-N., Cervek M., Cardenas D.M., Le Bricon T., Debiton E., Samuels S.E., Madelmont J.C., Attaix D. Chemotherapy inhibits skeletal muscle ubiquitin-proteasome-dependent proteolysis. Cancer Research. 62:2002;2771-2777.
37. Tischler M.E., Desautels M., Goldberg A.L. Does leucine, leucyl-tRNA, or some metabolite of leucine regulate protein synthesis and degradation in skeletal and cardiac muscle? Journal of Biological Chemistry. 257:1982;1613-1621.
38. Van Nocker S., Sadis S.Q., Rubin D.M., Glickman M., Fu H.Y., Coux O., Wefes I., Finley D., Vierstra R.D. The multiubiquitin-chain-binding protein mcb1 is a component of the 26S proteasome in saccharomyces cerevisiae and plays a nonessential, substrate specific role in protein turnover. Molecular and Cellular Biology. 16:1996;6020-6028.
39. 2+-activated, and ubiquitin-proteasome proteolytic pathways. Journal of Clinical Investigation. 97:1996;1610-1617.
40. Williams A.B., Decourten-Myers G.M., Fischer J.E., Luo G., Sun X., Hasselgren P.O. Sepsis stimulates release of myofilaments in skeletal muscle by a calcium-dependent mechanism. FASEB Journal. 13:1999;1435-1443.
41. Wing S.S., Goldberg A.L. Glucocorticoids activate the ATP-ubiquitin-dependent proteolytic system in skeletal muscle during fasting. American Journal of Physiology. 264:1993;E668-E676.